SOX2 inhibits LLGL2 polarity protein in esophageal squamous cell carcinoma via miRNA-142-3p

References

• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412. doi:10.1016/S0140-6736(12)60643-6.
   Web of Science ®Google Scholar
• Liu K, Zhao T, Wang J, Chen Y, Zhang R, Lan X, Que J. Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer. Cancer Lett. 2019;458:21–28. doi:10.1016/j.canlet.2019.05.018.
   PubMed Web of Science ®Google Scholar
• Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, Zhang F, Zhao Z-R, Li Z-T, Liu Z-Y, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46(10):1097–1102. doi:10.1038/ng.3076.
   Web of Science ®Google Scholar
• Qu Y, Zhang S, Cui L, Wang K, Song C, Wang P, et al. Two novel polymorphisms in PLCE1 are associated with the susceptibility to esophageal squamous cell carcinoma in Chinese population. Dis Esophagus. 2017;30(1):1–7. doi:10.1111/dote.12463.
   Web of Science ®Google Scholar
• Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–95. doi:10.1038/nature13176.
   PubMed Web of Science ®Google Scholar
• Wu C, Wang Z, Song X, Feng X-S, Abnet CC, He J, Hu N, Zuo X-B, Tan W, Zhan Q, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet. 2014;46(9):1001–1006. doi:10.1038/ng.3064.
   PubMed Web of Science ®Google Scholar
• Liu K, Jiang M, Lu Y, Chen H, Sun J, Wu S, Ku W-Y, Nakagawa H, Kita Y, Natsugoe S, et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell. 2013;12(3):304–315. doi:10.1016/j.stem.2013.01.007.
   PubMed Web of Science ®Google Scholar
• Que J, Luo X, Schwartz RJ, Hogan BL. Multiple roles for Sox2 in the developing and adult mouse trachea. Development. 2009;136(11):1899–1907. doi:10.1242/dev.034629.
   Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi:10.1016/j.cell.2007.11.019.
   PubMed Web of Science ®Google Scholar
• Trisno SL, Philo KED, McCracken KW, Cata EM, Ruiz-Torres S, Rankin SA, Han L, Nasr T, Chaturvedi P, Rothenberg ME, et al. Esophageal organoids from human pluripotent stem cells delineate Sox2 functions during esophageal specification. Cell Stem Cell. 2018;23(4):501–515.e7. doi:10.1016/j.stem.2018.08.008.
   Web of Science ®Google Scholar
• Gen Y, Yasui K, Nishikawa T, Yoshikawa T. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci. 2013;104(7):810–816. doi:10.1111/cas.12155.
   Web of Science ®Google Scholar
• Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–1242. doi:10.1038/ng.465.
   PubMed Web of Science ®Google Scholar
• Liu K, Lin B, Zhao M, Yang X, Chen M, Gao A, Liu F, Que J, Lan X. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5):1264–1271. doi:10.1016/j.cellsig.2013.02.013.
   PubMed Web of Science ®Google Scholar
• Huser L, Novak D, Umansky V, Altevogt P, Utikal J. Targeting SOX2 in anticancer therapy. Expert Opin Ther Targets. 2018;22(12):983–991. doi:10.1080/14728222.2018.1538359.
   Web of Science ®Google Scholar
• Ji J, Yu Y, Li ZL, Chen MY, Deng R, Huang X, Wang G-F, Zhang M-X, Yang Q, Ravichandran S, et al. XIAP limits autophagic degradation of Sox2 and is a therapeutic target in nasopharyngeal carcinoma stem cells. Theranostics. 2018;8(6):1494–1510. doi:10.7150/thno.21717.
   Web of Science ®Google Scholar
• Jia Y, Gu D, Wan J, Yu B, Zhang X, Chiorean EG, et al. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene. 2019;38(10):1764–1777. doi:10.1038/s41388-018-0553-0.
   Web of Science ®Google Scholar
• Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73. doi:10.1186/1476-4598-11-73.
   PubMed Web of Science ®Google Scholar
• Yoo YA, Vatapalli R, Lysy B, Mok H, Desouki MM, Abdulkadir SA. The role of castration-resistant Bmi1+Sox2+ cells in driving recurrence in prostate cancer. J Natl Cancer Inst. 2019;111(3):311–321. doi:10.1093/jnci/djy142.
   Google Scholar
• Liu K, Xie F, Zhao T, Zhang R, Gao A, Chen Y, Li H, Zhang S, Xiao Z, Li J, et al. Targeting SOX2 protein with peptide aptamers for therapeutic gains against esophageal squamous cell carcinoma. Mol Ther. 2020;28(3):901–913. doi:10.1016/j.ymthe.2020.01.012.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714. doi:10.1038/nrg2634.
   Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–269. doi:10.1038/nrc1840.
   Web of Science ®Google Scholar
• Liu A, Zhu J, Wu G, Cao L, Tan Z, Zhang S, Jiang L, Wu J, Li M, Song L, et al. Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer. 2017;16(1):106. doi:10.1186/s12943-017-0669-9.
   Web of Science ®Google Scholar
• Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, Allred C, Muthuswamy SK. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell. 2008;135(5):865–878. doi:10.1016/j.cell.2008.09.045.
   Web of Science ®Google Scholar
• Liu K, Xie F, Gao A, Zhang R, Zhang L, Xiao Z, Hu Q, Huang W, Huang Q, Lin B, et al. SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 2017;16(1):62. doi:10.1186/s12943-017-0632-9.
   PubMedGoogle Scholar
• Jiang M, Ku W-Y, Zhou Z, Dellon ES, Falk GW, Nakagawa H, Wang M-L, Liu K, Wang J, Katzka DA, et al. BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. J Clin Invest. 2015;125(4):1557–1568. doi:10.1172/JCI78850.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF, Huang WZ, Wang W-S, Jiang T-F, Wu B-L, Li E-M, et al. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surg Oncol. 2012;105(2):175–182. doi:10.1002/jso.22066.
   Web of Science ®Google Scholar
• Kashyap A, Zimmerman T, Ergul N, Bosserhoff A, Hartman U, Alla V, Bataille F, Galle PR, Strand S, Strand D, et al. The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis. Oncogene. 2013;32(11):1396–1407. doi:10.1038/onc.2012.162.
   PubMed Web of Science ®Google Scholar
• Fong H, Hohenstein KA, Donovan PJ. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells. 2008;26(8):1931–1938. doi:10.1634/stemcells.2007-1002.
   Web of Science ®Google Scholar
• Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun. 2015;6:6411. doi:10.1038/ncomms7411.
   PubMed Web of Science ®Google Scholar
• Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, Liu Y, Li X, Xiang R, Li N, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network. Cancer Lett. 2013;336(2):379–389 . doi:10.1016/j.canlet.2013.03.027.
   Web of Science ®Google Scholar
• Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, Markowitz D, Reisfeld RA, Luo Y. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer. 2011;104(9):1410–1417. doi:10.1038/bjc.2011.94.
   PubMed Web of Science ®Google Scholar
• Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011;71(9):3410–3421. doi:10.1158/0008-5472.CAN-10-3340.
   Web of Science ®Google Scholar
• Jia Y, Gu D, Wan J, Yu B, Zhang X, Chiorean EG, et al. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene. 2019;38(10):1764–1777. doi:10.1038/s41388-018-0553-0.
   PubMed Web of Science ®Google Scholar
• Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, Menon R, Nikolov P, Petersen K, Beschorner C, et al. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol. 2011;42(8):1078–1088. doi:10.1016/j.humpath.2010.11.010.
   PubMed Web of Science ®Google Scholar
• Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96(8):1293–1301. doi:10.1038/sj.bjc.6603696.
   PubMed Web of Science ®Google Scholar
• Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target. Signal Transduct Target Ther. 2020;5(1):135. doi:10.1038/s41392-020-00242-3.
   Web of Science ®Google Scholar
• Hofken T, Schiebel E. A role for cell polarity proteins in mitotic exit. EMBO J. 2002;21(18):4851–4862. doi:10.1093/emboj/cdf481.
   Web of Science ®Google Scholar
• Bilder D, Schober M, Perrimon N. Integrated activity of PDZ protein complexes regulates epithelial polarity. Nat Cell Biol. 2003;5(1):53–58. doi:10.1038/ncb897.
   Web of Science ®Google Scholar
• Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene. 2008;27(55):6958–6969. doi:10.1038/onc.2008.346.
   Web of Science ®Google Scholar
• Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008;68(2):537–544. doi:10.1158/0008-5472.CAN-07-5682.
   PubMed Web of Science ®Google Scholar
• Halaoui R, McCaffrey L. Rewiring cell polarity signaling in cancer. Oncogene. 2015;34(8):939–950. doi:10.1038/onc.2014.59.
   Web of Science ®Google Scholar
• Li YF, Chen DQ, Jin L, Liu JJ, Li YC, Su ZM, QI Z, SHI M, JIANG Z, YANG S, et al. Oncogenic microRNA-142-3p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Oncol Lett. 2016;11(2):1235–1241. doi:10.3892/ol.2015.4021.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kondo K, Kitajima K, Muraoka M, Nozawa A, Hara T. Tumor-suppressive function of protein-tyrosine phosphatase non-receptor type 23 in testicular germ cell tumors is lost upon overexpression of miR142-3p microRNA. J Bio Chem. 2013;288(33):23990–23999. doi:10.1074/jbc.M113.478891.
   Web of Science ®Google Scholar
• Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJF, Sültmann H, et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer. 2013;80(2):223–227. doi:10.1016/j.lungcan.2013.01.013.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Ghasabi M, Shirjang S, Dehghan R, Montazeri V, Holmskov U, Kazemi T, Duijf P, Gjerstorff M, et al. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. J Cell Physiol. 2019;234(6):9816–9825. doi:10.1002/jcp.27670.
   PubMed Web of Science ®Google Scholar
• Liang L, Fu J, Wang S, Cen H, Zhang L, Mandukhail SR, Du L, Wu Q, Zhang P, Yu X, et al. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B. 2020;10(6):1036–1046. doi:10.1016/j.apsb.2019.11.009.
   PubMed Web of Science ®Google Scholar
• Cao F, Miao Y, Xu K, Liu P. Lethal (2) giant larvae: an indispensable regulator of cell polarity and cancer development. Int J Biol Sci. 2015;11(4):380–389. doi:10.7150/ijbs.11243.
   Web of Science ®Google Scholar
• Sonawane M, Martin-Maischein H, Schwarz H, Nusslein-Volhard C. Lgl2 and E-cadherin act antagonistically to regulate hemidesmosome formation during epidermal development in zebrafish. Development. 2009;136(8):1231–1240. doi:10.1242/dev.032508.
   Web of Science ®Google Scholar
• Nakajima Y, Gibson MC. Epithelial cell division: aurora kicks Lgl to the cytoplasmic curb. Curr Biol. 2015;25(1):R43–5. doi:10.1016/j.cub.2014.11.052.
   Web of Science ®Google Scholar
• Portela M, Parsons LM, Grzeschik NA, Richardson HE. Regulation of Notch signaling and endocytosis by the Lgl neoplastic tumor suppressor. Cell Cycle. 2015;14(10):1496–1506 doi:10.1080/15384101.2015.1026515.
   Web of Science ®Google Scholar
• Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, et al. Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Modern Pathol. 2009;22(7):977–984. doi:10.1038/modpathol.2009.68.
   Web of Science ®Google Scholar
• Lisovsky M, Dresser K, Woda B, Mino-Kenudson M. Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Hum Pathol. 2010;41(6):902–909. doi:10.1016/j.humpath.2009.12.004.
   Web of Science ®Google Scholar
• Nam KH, Kim MA, Choe G, Kim WH, Lee HS. Deregulation of the cell polarity protein Lethal giant larvae 2 (Lgl2) correlates with gastric cancer progression. Gastric Cancer. 2014;17(4):610–620. doi:10.1007/s10120-013-0324-0.
   Web of Science ®Google Scholar
• Imamura N, Horikoshi Y, Matsuzaki T, Toriumi K, Kitatani K, Ogura G, Masuda R, Nakamura N, Takekoshi S, Iwazaki M, et al. Localization of aPKC lambda/iota and its interacting protein, Lgl2, is significantly associated with lung adenocarcinoma progression. Tokai J Exp Clin Med. 2013;38(4):146–158.
   Google Scholar
• Reischauer S, Levesque MP, Nusslein-Volhard C, Sonawane M, Mullins MC. Lgl2 Executes Its Function as a Tumor Suppressor by Regulating ErbB Signaling in the Zebrafish Epidermis. PLoS Genet. 2009;5(11):e1000720. doi:10.1371/journal.pgen.1000720.
   Web of Science ®Google Scholar
• Saito Y, Li L, Coyaud E, Luna A, Sander C, Raught B, Asara JM, Brown M, Muthuswamy SK. LLGL2 rescues nutrient stress by promoting leucine uptake in ER(+) breast cancer. Nature. 2019;569(7755):275–279. doi:10.1038/s41586-019-1126-2.
   Web of Science ®Google Scholar
• Li Y, Kong F, Shao Q, Wang R, Hu E, Liu J, et al. YAP expression and activity are suppressed by S100A7 via p65/NFkappaB-mediated repression of DeltaNp63. Mol Cancer Res. 2017;15(12):1752–1763 doi:10.1158/1541-7786.MCR-17-0349.
   Web of Science ®Google Scholar
• Mayama A, Takagi K, Suzuki H, Sato A, Onodera Y, Miki Y, Sakurai M, Watanabe T, Sakamoto K, Yoshida R, et al. OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma. Cancer Sci. 2018;109(10):3350–3359. doi:10.1111/cas.13770.
   Web of Science ®Google Scholar
• van der Kaaij RT, Voncken FEM, van Dieren JM, Snaebjornsson P, Korse CM, Grootscholten C, et al. Elevated pretreatment CEA and CA19-9 levels are related to early treatment failure in esophageal adenocarcinoma. Am J Clin Oncol. 2019;42(4):345–350. doi:10.1097/COC.0000000000000525.
   Web of Science ®Google Scholar
• Sells E, Pandey R, Chen H, Skovan BA, Cui H, Ignatenko NA. Specific microRNA-mRNA regulatory network of colon cancer invasion mediated by tissue kallikrein-related peptidase 6. Neoplasia. 2017;19(5):396–411. doi:10.1016/j.neo.2017.02.003.
   Web of Science ®Google Scholar
• Li W, Zhang Z, Zhao W, Han N. Transglutaminase 3 protein modulates human esophageal cancer cell growth by targeting the NF-kappaB signaling pathway. Oncol Rep. 2016;36(3):1723–1730. doi:10.3892/or.2016.4921.
   Web of Science ®Google Scholar
• Lin S, Liu K, Zhang Y, Jiang M, Lu R, Folts CJ, et al. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma. Cell Signal. 2018;51:222–232. doi:10.1016/j.cellsig.2018.08.008.
   PubMed Web of Science ®Google Scholar
• Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, Logan CV, Newbury LJ, Kamath BM, Ling S, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46(4):326–328. doi:10.1038/ng.2918.
   PubMed Web of Science ®Google Scholar
• Zhou S, Hertel PM, Finegold MJ, Wang L, Kerkar N, Wang J, Wong LJC, Plon SE, Sambrotta M, Foskett P, et al. Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. Hepatology. 2015;62(6):1914–1916. doi:10.1002/hep.27872.
   PubMed Web of Science ®Google Scholar
• Orlandella FM, Mariniello RM, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, et al. Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 α/β pathways. Mol Carcinog. 2019;58(7):1181–1193. doi:10.1002/mc.23001.
   PubMed Web of Science ®Google Scholar